Fulgent Genetics

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fulgent Genetics surpasses revenue targets, eyes precision medicine growth

Fulgent Genetics delivered strong financial performance in 2022, exceeding revenue guidance and positioning for continued growth in 2023 across key business segments.
The company's strategic focus on precision medicine, oncology, and pharma services, coupled with a robust cash position, sets the stage for future expansion and innovation.
Challenges in margin improvement and reimbursement highlight areas for operational refinement, while opportunities in acquisitions and menu expansion offer avenues for sustained growth.

Fulgent Genetics reports robust Q1 revenue growth and strategic advancements

Fulgent Genetics delivered strong revenue growth in Q1 2023, with a focus on core business strength and promising developments in key drug candidates and business segments.
While facing challenges in operational efficiency and negative Adjusted EBITDA, the company maintains a strong cash position and is optimistic about future opportunities.
Strategic acquisitions, market expansion, and continued margin improvement are key areas of focus for Fulgent Genetics to drive sustained growth and profitability.

Fulgent Genetics reports record Q2 revenue and advances in cancer treatment

Fulgent Genetics (FLGT) delivered a strong performance in Q2 2023, with record core revenue and promising developments in cancer treatment.
The company's focus on innovation, operational efficiency, and margin improvement underscores a commitment to sustainable growth.
While facing challenges in cost management and competitive dynamics, Fulgent Genetics is well-positioned to capitalize on opportunities through technology and strategic initiatives.

Fulgent Genetics reports robust Q3 earnings, eyes growth in precision diagnostics

Fulgent Genetics demonstrated solid financial performance in Q3 2023, with strong core revenue and improved gross margins. The company continues to focus on precision diagnostics and therapeutic development, presenting growth opportunities. Challenges include fluctuations in Pharma services revenue and COVID-19 testing demand.

Fulgent Genetics surpasses Q4 revenue targets, eyes FDA regulatory landscape

Fulgent Genetics delivered strong Q4 results, exceeding revenue guidance and showcasing growth in core revenue.
The company faces challenges in BioPharma Services and Anatomic Pathology but is investing in operations and AI for improvement.
Opportunities lie in Precision Diagnostics growth, market share gains in carrier screening, and adapting to FDA oversight of laboratory developed tests.
Management's confidence in quality systems and readiness to pursue FDA approval for high-risk tests position Fulgent Genetics for regulatory changes.

Fulgent Genetics excels in Q1 2024 with strong revenue growth

Fulgent Genetics delivered strong Q1 results driven by precision diagnostics and therapeutic development progress.
While facing challenges in managing expenses, the company showcased financial discipline and innovation in new product launches.
With a focus on improving margins and capturing market opportunities, Fulgent Genetics aims for continued growth and profitability in 2024.

Fulgent Genetics reports robust Q2 revenue, invests in innovative treatments

Fulgent Genetics demonstrated solid revenue performance in Q2, driven by core business growth in key segments.
While facing profitability challenges, the company continues to invest in innovative treatments and technology.
Maintaining a strong cash position and focusing on strategic growth areas position Fulgent Genetics for future success.
Balancing cost management with revenue growth will be crucial for the company's financial health and long-term sustainability.

Fulgent Genetics reports robust Q3 earnings, eyes strategic growth opportunities

Fulgent Genetics demonstrated solid revenue growth and financial stability in Q3 2024.
The company's focus on precision diagnostics and therapeutic development shows promise for future growth.
Challenges lie in maintaining margins, managing expenses, and optimizing the VA contract's impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer question.

Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024

Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Results: Total Revenue of $70.5 million Core Revenue1 grew 21% year-over-year to $66.5 million GAAP loss of $128.1 million, or $4.30 per share Non-GAAP income.

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

Fulgent Genetics spent the past 2 years digesting the Covid cliff, which wiped out 80% of its market capitalization since the 2021 peak. The company is about to hit an inflection point, as 2024 will be the year revenues return to growth while margins expand. The Fulgent Pharma business acquired at the end of 2022 will remain a drag near term but offers significant mid- to long-term upside potential.

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the res.

Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024

Cooper Companies

Testing offers CBR families the opportunity to proactively seek additional information about their child's health ‍TRUMBULL, Conn. and EL MONTE, Calif.

Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing

Exact Sciences

23andMe

If you're searching for digital health stocks to add to your portfolio, look no further. Technological innovation is leading to the increased digitalization and personalization of healthcare.

The 3 Best Digital Health Stocks for Personalized Medicine

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023. These representatives of the company will conduct a presentation beginning at approximately 12:00 p.m. Easter.

Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA. “These data support our mission to build a holistic platform to provide comprehensive solutio.

Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Brandon Perthuis - CCO Paul Kim - CFO Lawrence Weiss - Chief Medical Officer Conference Call Participants David Westenberg - Piper Sandler Andrew Cooper - Raymond James Operator Hello, and welcome to the Fulgent Genetics Q3 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation.

Fulgent Genetics, Inc. (FLGT) Q3 2023 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to earnings of $0.32 per share a year ago.

Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023. Third Quarter 2023 Results: Total Revenue of $85 million Core Revenue1 grew 17% year-over-year to $66 million GAAP loss of $13.1 million, or $0.44 per share Non-GAAP loss of $11.7 million, or $0.

Fulgent Reports Third Quarter 2023 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023. Details on Fulgent's poster presentations at SITC are as follows: T.

Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its third quarter 2023 financial results before the market opens on Friday, November 3, 2023. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer que.

Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023

Fulgent Genetics saw robust Q2 revenue growth at $68M but struggled with a GAAP loss of $11.2M, suggesting strategic investments. The firm boasts significant liquidity ($846.8M), allowing for potential acquisitions or growth initiatives, yet operational expenses raise questions. Investment Recommendation: Despite market pullback and operational costs, strong fundamentals and growth potential support a continued "Buy" recommendation.

Fulgent Genetics: Navigating Post-COVID Growing Pains

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2023 Earnings Conference Call August 4, 2023 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Lawrence Weiss - Chief Medical Officer Conference Call Participants Dan Leonard - Credit Suisse David Westenberg - Piper Sandler Andrew Cooper - Raymond James Operator Hello and welcome to the Fulgent Genetics Q2 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation.

Fulgent Genetics, Inc. (FLGT) Q2 2023 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to earnings of $0.78 per share a year ago.

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2023. Second Quarter 2023 Results: Total Revenue of $68 million Core Revenue1 grew 48% year-over-year to $67 million GAAP loss of $11.2 million, or $0.38 per share Non-GAAP loss of $2.4 million, or $0.08.

Fulgent Reports Second Quarter 2023 Financial Results

Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT's stock presents mixed signals with potential undervaluation, despite negative earnings forecasted till 2025. For Q2 earnings, monitor the core revenue performance, updates on reproductive health and oncology initiatives, and changes in cash reserves and debt.

Fulgent Genetics: Post-Pandemic Devaluing Appears Overdone

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its second quarter 2023 financial results before the market opens on Friday, August 4, 2023. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer ques.

Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023

NVIDIA

Fulgent Genetics is seeing its base of revenue shift to non-COVID testing products. It's also starting to develop medicines in house after a recent acquisition.

Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from a Phase 1/1b clinical study of FID-007 in treating various solid tumors was presented in a poster session at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 3, 2023. Of 40 evaluable patients with weekly dose le.

Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers

23andMe is scaling up its pipeline with the help of its collaborators. Fulgent Genetics is rapidly building its oncology testing business.

Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

BioNTech SE

Certain biotechs that hit it big early during the pandemic are now undervalued. BioNTech is preparing for a rapid pace of new drug launches.

2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that Phase 1/1b clinical data on its lead therapeutic development candidate, FID-007, to treat various solid tumors, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at 8:00 a.m. Central Time on June 3, 2023 in Chicago, Ill.

News for Fulgent Genetics Stock (FLGT)